CVAC Skyrocketed

Mon, Aug 17, 2020 at 06:31 PM

CVAC (CVAC:NASDAQ) rocketted at $77.2, a gain of 38.1%. The stock appeared on our News Catalysts scanner on Mon 17 Aug 20 at 10:31 AM in the 'MISCELLANEOUS' category.

About CVAC (CVAC:NASDAQ)

CureVac BV a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company's product portfolio includes clinical and preclinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in a Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2), for which the company initiated a Phase 1 clinical trial.

Top 10 Gainers:

Comstock Mining Inc. (LODE:NYSEMKT), 83.54%
LMP Automotive Holdings, Inc. (LMPX:NASDAQ), 69.68%
RISE Education Cayman Ltd (REDU:NASDAQ), 47.96%
LSB Industries, Inc. (LXU:NYSE), 40.28%
Stein Mart, Inc. (SMRT:NASDAQ), 39.03%
CVAC (CVAC:NASDAQ), 38.1%
ClearOne, Inc. (CLRO:NASDAQ), 31.03%
Altisource Asset Management Corporation (AAMC:NYSEMKT), 30.73%
Pacific Ethanol, Inc. (PEIX:NASDAQ), 30.41%
China Ceramics Co., Ltd. (CCCL:NASDAQ), 29.84%